Cognito Therapeutics Announces Oral Presentation at 2024 American Academy of Neurology (AAN) Annual Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#alzheimers—Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, announced today that data from the open-label extension (OLE) study of Spectris™, a potential disease modifying therapy for the treatment of Alzheimer’s Disease, will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, held April 13-18, 2024, in Denver, CO.

The OLE study was a separate 12-month protocol that followed the six-month OVERTURE randomized clinical trial, in which 83% of OVERTURE study participants enrolled. The OLE enabled the evaluation of extended Spectris™ treatment over 18 months, employing a delayed-start analysis to evaluate the potential of Spectris™ as a disease modifying therapy.

AAN 2024 Presentation Details:

Title: Cognito’s non-invasive medical device demonstrates durable effects on activities of daily living through OVERTURE open-label extension study

Format: Oral (Abstract #5238, Presentation #002)

Date/Time: Sunday, April 14, at 2:30 p.m. MT

Session: N2: Neuroscience in the Clinic: Neuromodulation: From Bench to Bedside

Presenter: Ralph Kern, M.D., MHSc, Chief Medical Officer of Cognito Therapeutics

For more information about the AAN abstract, visit https://www.aan.com/msa/Public/Events/AbstractDetails/55258.

About Cognito Therapeutics

Cognito Therapeutics is a late clinical-stage neurotechnology company dedicated to the development of transformative disease-modifying therapies for neurodegenerative diseases. Cognito’s proprietary approach targets dysregulated network activity in the brain and has shown meaningful outcomes in Alzheimer’s patients. Cognito’s lead product, Spectris, employs a proprietary non-invasive method designed to evoke increased gamma frequency brain activity using auditory and visual neuromodulation to slow the rate of brain atrophy and loss of brain function. Cognito’s mission is to develop a new class of technology-based therapeutic interventions to transform the lives of patients with neurodegenerative diseases. Cognito is headquartered in Cambridge, MA. For more information, visit www.cognitotx.com.

Contacts

Kimberly Ha

KKH Advisors

917-291-5744

[email protected]